A novel lipophilic amiloride derivative efficiently kills chemoresistant breast cancer cells

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Amiloride derivatives show promise as anti-cancer agents, targeting tumor cells resistant to conventional therapies.
• A key limitation is their modest cytotoxic potency, hindering clinical application.
• Developing more potent amiloride analogs is crucial for therapeutic advancement.

Purpose of the Study:

• To synthesize and evaluate novel amiloride derivatives for enhanced anti-cancer activity.
• To investigate the structure-activity relationships governing amiloride derivative cytotoxicity.
• To assess the efficacy of potent derivatives against diverse breast cancer models and drug-resistant cell lines.

Main Methods:

• Synthesis of ten novel amiloride derivatives.
• Cytotoxicity assays using MCF7, SKBR3, and MDA-MB-231 breast cancer cell lines.
• Evaluation of drug lipophilicity and its correlation with cytotoxicity.
• Assessment of preferential cytotoxicity in mouse mammary tumor organoids.
• Testing efficacy in a mouse model of metastatic breast cancer.

Main Results:

• Cytotoxicity is linked to an intact guanidine group and increased drug lipophilicity.
• The derivative LLC1 exhibits single-digit micromolar cytotoxicity against major breast cancer subtypes.
• LLC1 demonstrates preferential cytotoxicity against tumor organoids over normal cells.
• LLC1 is effective against cells with transient and sustained chemotherapeutic resistance.
• Limited anti-tumor effects were observed in a metastatic breast cancer mouse model.

Conclusions:

• Amiloride derivatives can be optimized for preferential breast tumor cell cytotoxicity.
• Lipophilicity and guanidine group integrity are key factors for enhanced potency.
• LLC1 represents a promising lead compound, though further in vivo studies are warranted.
• These findings provide a framework for developing next-generation amiloride-based cancer therapies.